Soaanz (Torsemide) Patent Expiration, LOE Window & CMS Spending

Soaanz (Torsemide) by Sarfez: FDA Orange Book LOE 2033-10-06, 6 AB generics, $5.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSarfez
FDA Application & PathwayN213218 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-10-06
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$5.2M
2024 Medicare Part D Spend$5.2M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel